Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Placental barrier against COVID-19

Shihoko Komine-Aizawa*, Kazuhide Takada, Satoshi Hayakawa

Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Pregnancy
Placental barrier

ABSTRACT

Vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and possible induction of pregnancy complications, including miscarriage, fetal malformations, fetal growth restriction and/or stillbirth, are serious concerns for pregnant individuals with COVID-19. According to clinical information, the incidence of vertical transmission of SARS-CoV-2 is limited to date. However, even if a neonate tests negative for SARS-CoV-2, frequent abnormal findings, including fetal and maternal vascular malperfusion, have been reported in cases of COVID-19-positive mothers. Primary receptor of SARS-CoV-2 is estimated as angiotensin-converting enzyme 2 (ACE2). It is highly expressed in maternal-fetal interface cells, such as syncytiotrophoblasts, cytotrophoblasts, endothelial cells, and the vascular smooth muscle cells of primary and secondary villi. However other route of transplacental infection cannot be ruled out. Pathological examinations have demonstrated that syncytiotrophoblasts are often infected with SARS-CoV-2, but fetuses are not always infected. These findings suggest the presence of a placental barrier, even if it is not completely effective. As the frequency and molecular mechanisms of intrauterine vertical transmission of SARS-CoV-2 have not been determined to date, intensive clinical examinations by repeated ultrasound and fetal heart rate monitoring are strongly recommended for pregnant women infected with COVID-19. In addition, careful investigation of placental samples after delivery by both morphological and molecular methods is also strongly recommended.

1. Introduction

The outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has emerged as the most critical global public health problem in 2020. For pregnant individuals infected with SARS-CoV-2, vertical transmission and subsequent pregnancy complications, such as miscarriage, fetal malformations, fetal growth restriction and/or stillbirth, are serious concerns.

It is well known that some viral species can cause congenital viral infections and affect the health status of the fetus [1]. For instance, rubella virus infection during pregnancy causes congenital rubella syndrome, which includes cataracts, cardiac abnormalities and sensorineural deafness, and genital herpes simplex virus infection during vaginal delivery presents a risk of neonatal herpes simplex virus (HSV) infections. The transmission route of a virus to the feto-maternal unit depends on the viral species. Diverse viruses can infect several components of the feto-maternal unit, including syncytiotrophoblasts, cytotrophoblasts, endothelial cells, hematopoietic cells, and the fetal membrane.

From the limited information, the incidence of vertical transmission of SARS-CoV-2 has been considered rare; however, some cases have been reported [2–4]. At this time, we do not have specific medicines or effective vaccines for COVID-19. Therefore, to reduce the incidence of vertical transmission of COVID-19, it is important to understand the mechanisms of SARS-CoV-2 intrauterine infection. In this review, we discuss the possibility of vertical transmission of COVID-19, particularly regarding the placental barrier.

2. Placental pathology in COVID-19-positive mothers

The establishment of vertical transmission of COVID-19 is limited to date. According to a systematic review by Lamouroux, 4 neonates among 68 deliveries and 71 neonates were positive for COVID-19 [5]. A systematic review by Yang showed that among 83 neonates, 9 had evidence of SARS-CoV-2 infection [6]. Zaigham et al. reviewed 18 articles reporting data from 108 pregnancies and found one neonatal death and one intrauterine fetal demise (IUFD), in which vertical transmission could not be ruled out [7].
However, frequent abnormal findings in placental pathology have been reported among COVID-19-positive mothers (Table 1). The most common finding is vascular malperfusion. Mulvey et al. investigated five placentas from COVID-19 patients who delivered at term [8]. All five placentas showed fetal vascular malperfusion (FVM) with multiple thromboses [8]. Similarly, Baergen et al. reported that among 20 cases, FVM was observed in 9 cases [9]. Shanes et al. examined 16 placentas from patients with COVID-19, including a second-trimester placenta after IUFD at 16 weeks of gestation [10]. Among 15 third-trimester placentas, FVM and maternal vascular malperfusion were present in 12 cases [10]. The placenta from the patient with IUFD showed villous edema and a retroplacental hematoma [10]. Findings such as thrombosis, intramural fibrin deposition, villous stromal-vascular karyorhexis, and villous infarction were commonly observed [8–10]. Interestingly, acute and chronic inflammatory reactions were rarely observed [9–10]. This finding could be explained by the presence of regulatory cytokines produced by placental and decidual immune cells. Furthermore, the active replication and release of the SARS-CoV-2 cause pyroptosis [11], which is a highly inflammatory pathway in the infected cells. In human trophoblast, pyroptosis also reported as a critical inflammatory form to induce adverse pregnant outcomes [12]. One possible hypothesis is SARS-CoV-2 can infect and replicate in the trophoblast cells but cannot be released. Therefore, inflammatory findings might be hardly observed in the placenta with SARS-CoV-2. However, the placentas of SARS-CoV-2-positive neonates showed chronic intervillositis with the presence of macrophages [3].

3. Detection of SARS-CoV-2 antigens in the placental tissue of COVID-19 positive mothers

The placenta functions as a physical barrier between a mother and a fetus. Specifically, syncytiotrophoblasts are the front line of defense against vertical transmission because maternal and fetal tissues are separated by syncytiotrophoblast layers. Currently, there are several reports suggesting placental infection with SARS-CoV-2 (Table 2). Patane et al. reported two cases of COVID-19 vertical transmission with placental pathological findings [3]. Through in situ hybridization, SARS-CoV-2 spike protein mRNA was observed in the syncytiotrophoblasts of placentas obtained from mothers with COVID-19-positive neonates, while no SARS-CoV-2 spike protein mRNA was observed in the positive mother’s placenta with a COVID-19-negative neonate [3]. Algarroba et al. presented electron microscopy findings of the placenta of a COVID-19-positive patient. They suggested the localization of coronaviral virions in the cytoplasm of syncytiotrophoblasts despite the neonate testing negative for COVID-19 [13]. Penfield et al. reported that three of 11 COVID-19-positive placental swabs were positive according to SARS-CoV-2 PCR testing; however, all of the neonates were negative according to SARS-CoV-2 RNA testing, and none demonstrated clinical symptoms of COVID-19 infection [14]. Mulvey et al. reported that viral spike protein and viral RNA staining within COVID-19-positive placental tissue was rare [8]. These reports suggest that even though SARS-CoV-2 was present in the placenta, the incidence of vertical transmission may be limited. We need to investigate the maternal-fetal interface in SARS-CoV-2 infection cases in more detail.

4. The expression of angiotensin-converting enzyme 2 (ACE2) in the feto-placental unit

ACE2 is a zinc metalloprotease attached to the cell membrane. The main function of ACE2 is the regulation of blood pressure by catalyzing the hydrolysis of angiotensin I to angiotensin II. In addition, ACE2 works as a SARS-CoV-2 receptor for cell entry [15,16]. The expression of ACE2 is observed in various cells, including alveolar epithelial cells, endothelial cells, nephrocytes, and intestinal epithelial cells. Moreover, ACE2 is widely expressed in cells in the female genital tract and feto-placental unit, such as syncytiotrophoblasts, cytotrophoblasts, endothelial cells, and the vascular smooth muscles of primary and secondary villi [17]. A single-cell transcriptome study revealed ACE2 expression at the maternal-fetal interface and in fetal organs [18]. According to RefEx, which is the reference expression dataset, the expression of ACE2 in the reproductive tract is greater than that detected in the lung. Despite the finding that the mRNA expression level of ACE2 was higher in the early gestation placenta than the term placenta [19], clinical data suggest no evidence of an increase in spontaneous abortion cases in patients infected with SARS-CoV-2 in early pregnancy. The aberrant expression of ACE2 is associated with pregnancy complications. For instance, the expression of ACE2 in the arterial endothelium of the umbilical cord was increased in preeclamptic placentas compared with normal placentas [17]. This finding suggests that preeclampsia patients might be a high-risk group of COVID-19 vertical transmission. The expression levels of ACE2 are variable between trophoblast types and differentiation [19], further it can be influenced by pathophysiological conditions such as gestational diabetes mellitus (GDM) and preeclampsia. These changes must be examined carefully to evaluate possible risks of vertical transmission.

ACE2 is also expressed in the vaginal mucosa; however, SARS-CoV-2 was not detectable in the vaginal fluid of women with severe COVID-19 infections in several studies [20–22].

5. Mechanisms of vertical transmission

Although the precise mechanisms employed by SARS-CoV-2 to cross the placental barrier are unknown so far, the following possibilities have been considered: (i) direct infection of syncytiotrophoblasts and breach through the syncytial layers via ACE2 and Fc receptor (FcR), (ii) passage through the maternal circulation to extravillous trophoblasts or other placental cells, (iii) passage through maternal immune cells, and (iv) ascending infection via the maternal vaginal tract (Fig. 1). According to recent reports, SARS-CoV-2 mRNA or virions were detected in syncytiotrophoblasts [3,13], and transplacental infection of SARS-CoV-2 is

| Table 1 Placental pathology in COVID-19 positive mothers. |
|---------------------------------------------------------|
| Study        | N  | GA        | COVID-19 | Histological findings                      | Other findings               |
|--------------|----|-----------|----------|--------------------------------------------|------------------------------|
| 1 Mulvey et al. [7] | 5  | 38w–40w   | 0        | Thrombosis, Intraterine fibrin deposition, Villous stromal-vascular karyorhexis | Focal increase in perivillous fibrin, Chorangiosis, Meconium |
| 2 Bargen et al. [8] | 20 | 33w–40w   | 0        | Thrombosis, Intraterine fibrin deposition, Villous stromal-vascular karyorhexis | Focal increase in fibrin, Intervillous thrombus, Focal chorangiosis, Meconium, Maternal vascular malperfusion |
| 3 Shanes et al. [9] | 16 | 33w–40w   | 0        | Fetal vessel-mural fibrin, Clustered avascular villi, Delayed villous maturation, Chorangiosis | Maternal vascular malperfusion |
|              | 16w (IUFD) |          |          | Villous edema, Retroploental hematoma       |                              |

N, total number of placentas; GA, weeks of gestation; COVID-19, number of COVID-19-positive neonates; FVM, fetal vascular malperfusion.
strongly suggested. However, direct infection of syncytiotrophoblasts by SARS-CoV-2 must be rare because the incidence of viremia in symptomatic SARS-CoV-2-positive adults was approximately 1% [23]. In addition, the susceptibility and kinetics of SARS-CoV-2 in trophoblasts are not well known. We should continue careful observation of pregnant women with COVID-19 and promote in vitro studies with a trophoblast cell line or primary trophoblast.

Transmission during vaginal delivery is another possible route of SARS-CoV-2 infection of the neonate. Recent systematic reviews showed that 9.6% [6] to 21.9% [24] of COVID-19 pregnant patients delivered vaginally. A report from Italy concluded that vaginal delivery may be associated with a low risk of intrapartum SARS-CoV-2 transmission to the neonate [25]. In Italy, some researchers recommend routine SARS-CoV-2 PCR assay testing with nasopharyngeal, vaginal and rectal swabs in each pregnant patient before delivery to determine the indication of safe vaginal delivery for patients with negative PCR test results for vaginal and rectal samples [26]. However, the low sensitivity of PCR examination, as well as the financial cost, and limited medical resources make this approach impractical.

Another possible mechanism of vertical transmission is via maternal immune cells. SARS-CoV-2 was reported to infect T lymphocytes through spike protein-mediated membrane fusion [27], and maternal lymphocytes occasionally migrate into the fetal circulation, which is observed as microchimerism.

6. Diagnosis of vertical transmission

There have been several reports of vertical COVID-19 transmission based on positive IgM antibodies in cord blood samples collected at the time of delivery [22]. Due to its large molecular size, IgM cannot pass the placental barrier. Thus, the presence of specific anti-SARS-CoV-2 IgM antibodies suggests intrauterine infection [22]. However, due to the high false positive rates of antibody testing, we must be careful to correctly diagnose intrauterine infection for neonates without any symptoms or positive PCR test results. The detection of viral genomes or viral antigens in neonatal samples is stronger evidence of vertical transmission. However, the site of sampling is an important issue because neonates might be infected with SARS-CoV-2 via the maternal bloodstream. They are not expected to secrete viruses in the sputum, saliva or stools in high copy numbers without prominent inflammation.
7. Possible harms of COVID-19 infection in the early pregnancy

Fortunately, there have been little reports of COVID-19-induced early pregnancy losses, which was reported with SARS [28]. However, we have no information about the effects of SARS-CoV-2 on early embryogenesis and organogenesis. In the Zika virus (ZKV) endemic in 2015, an increase in neural malformations, including microcephaly, was reported several months after the local endemic in Brazil. In this sense, clinicians are requested to perform intensive ultrasound monitoring of the fetuses of mothers infected with COVID-19 in early and mid-pregnancy. Placental investigation after delivery by both morphological and molecular methods is also strongly recommended.

8. Viral and host immune factors that might affect vertical transmission

From its emergence in December 2019, SARS-CoV-2 has constantly been reported to act on the fetal-fetal and fetal-placental microcirculation. In addition, we have no information about viral infection in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors, Cell Death Dis. 10 (12) (2019) 927.

[11] M.Z. Tay, C.M. Poh, L. Renia, P.A. MacKay, L.F.P. Ng, The trinity of COVID-19: immunity, inflammation and intervention, Nat. Rev. Immunol. 20 (6) (2020) 363-374.
[12] S.H. Cheng, A. Nakashima, W.J. Huber, S. Davis, S. Banerjee, Z. Huang, S. Saito, Y. Sadowsky, S. Sharma, Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors, Cell Death Dis. 10 (12) (2019) 927.

9. Conclusion

To date, the clinical importance of vertical transmission of SARS-CoV-2 through the placenta remains controversial. The low incidence of COVID-19 vertical transmission may suggest that the placenta functions as a barrier even if it does not completely separate the maternal and fetal circulation. In addition, we have no information about viral factors that might affect the rates of in utero transmission. To confirm the mechanisms of vertical transmission and the placental barrier, extensive investigations are required.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgements

We thank American Journal Experts for English editing.

References

[1] M. Leon-Juarez, M. Martinez-Castillo, L.D. Gonzalez-Garcia, A.C. Helguera-Repetto, V. Zago-Clavellina, J. Garcia-Cordero, A. Flores-Pleguez, A. Herrero-Salazar, E.R. Vazquez-Martinez, E. Reyes-Munoz, Cellular and molecular mechanisms of viral infection in the human placenta, Pathog. Dis. 75 (7) (2017).
[2] M.C. Alzamora, T. Attie-Bitach, J. Martinovic, M. Lureze-Ville, Y. Ville, Evidence for and against vertical transmission for SARS-CoV-2 (COVID-19), Am. J. Obstet. Gynecol. (2020), https://doi.org/10.1016/j.ajog.2020.04.039.
[3] Z. Yang, Y. Liu, Vertical transmission of severe acute respiratory syndrome coronavirus 2: a systematic review, Am. J. Perinatol. (2020), https://doi.org/10.1055/a-1040-8723.
[4] S.A. Alarcon, M. Anderson, Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies, Acta Obstet. Gynecol. Scand. (2020), https://doi.org/10.1111/aogs.13867.
[5] J.J. Mulvey, C.M. Magro, L.X. Maou, G.J. Nuovo, R.N. Baergen, Analysis of complement deposition and viral RNA in placenta of COVID-19 patients, Am. J. Diagn. Pathol. 46 (2020) 151530.
[6] R.N. Baergen, D.S. Heller, Placental pathology in COVID-19 positive mothers: preliminary findings, Pediatr. Dev. Pathol. 23 (3) (2020) 177-180.
[7] E.D. Shanes, L.B. Mithal, S. Haider, A.S. Miller, COVID-19: placental pathology in COVID-19, Am. J. Clin. Pathol. (2020), https://doi.org/10.1016/j.ajcp.2020.05.023.
[8] A.C. Penfield, S.G. Brubaker, M.A. Limaye, J. Lighter, A.J. Ratner, K.M. Thomas, J.J. Mulvey, A.S. Roman, Cortical proliferation and fetal fetal vascular rare samples, Am. J. Obstet. Gynecol. MFM (2020) 100133, https://doi.org/10.1016/j.ajogmf.2020.100133.
[9] P. Zhou, X.L. Yang, X.G. Wang, B. Hu, L. Zhang, W. Zhang, H.R. Si, Y. Zhu, B. Li, C. L. Huang, H.D. Chen, J. Chen, Y. Luo, H. Guo, R.D. Jiang, M.Q. Liu, Y. Chen, X. R. Shen, X. Wang, X.S. Zheng, K. Zhao, Q.J. Chen, F. Deng, L.L. Liu, B. Yan, F. X. Zhan, Y.Y. Wang, G.F. Xiao, Z.L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature 579 (7798) (2020) 270-273.
[10] M. Hoffmann, H. Kleine-Weber, S. Schroder, N. Monti, S. Kruger, S. Reinke, T. Schneider, T.S. Schiergens, G. Herrler, H.N. Wu, A. Nitsche, M.A. Muller, C. Drosten, S. Pohlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020) 278-288 e8.
[11] G. Valdes, L.A. Neves, L. Anton, J. Corthorn, C. Chacon, A.M. Germain, D. Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Muller, C. Drosten, S. Pohlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020) 278-288 e8.
[12] G. Valdes, L.A. Neves, L. Anton, J. Corthorn, C. Chacon, A.M. Germain, D. Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Muller, C. Drosten, S. Pohlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020) 278-288 e8.
[13] M. Li, L. Chen, J. Zhang, C. Xiong, X. Li, The SARS-CoV-2 receptor ACE2 expression and localization of the human placental prorenin/renin-angiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis? Placenta 32 (12) (2011) 956-962.
[14] L. Qin, X. Liu, M. Xiao, J. Xie, W. Cao, Z. Liu, A. Morse, Y. Xie, T. Li, Z. Zhu, SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection, Clin. Infect. Dis. (2020), https://doi.org/10.1093/cid/ciaa235.
[15] C. Fan, D. Lei, C. Fang, C. Li, M. Wang, Y. Liu, Y. Bao, Y. Sun, J. Huang, Y. Guo, Y. Yu, S. Wang, Perinatal transmission of COVID-19 associated SARS-CoV-2: should we worry? Clin. Infect. Dis. (2020), https://doi.org/10.1093/cid/ciaa226.
[16] L. Dong, J. Tian, S. He, C. Zhu, J. Wang, C. Liu, J. Yang, Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn, J. Am. Med. Assoc. (2020), https://doi.org/10.1001/jama.2020.4621.
[17] W. Wang, Y. Xu, R. Gao, R. Lu, K. Han, G. Wu, W. Tan, Detection of SARS-CoV-2 in different types of clinical specimens, J. Am. Med. Assoc. (2020), https://doi.org/10.1001/jama.2020.3786.
[18] J. Juan, M.M. Gil, Z. Bone, Y. Zhang, H. Yang, L.C. Poon, Possible contamination of genital area: implications for sexual and vertical transmission routes, J. Eur. Acad. Dermatol. Venereol. (2020), https://doi.org/10.1111/jdv.16278.
[19] E. Ferrazzi, L. Frigerio, V. Savasi, P. Vergani, F. Preumato, S. Barresi, S. Bianchi, E. Ciriello, F. Facchinetti, M.T. Gervasi, E. Iurlaro, A. Kustermann, G. Mangili, F. Mosca, L. Patane, D. Spazzini, A. Pinollo, G. Troiano, M. Vignali, A. Villa, G. V. Zuccotti, F. Parazzini, I. Cetin, Vaginal delivery in SARS-CoV-2 infected pregnant women in Northern Italy: a retrospective analysis, BJOG (2020), https://doi.org/10.1111/1471-0528.16278.
[20] M. Delfino, M. Guida, A. Patri, L. Spirtito, L. Gallo, G. Fabbrocini, SARS-CoV-2 possible contamination of genital area: implications for sexual and vertical transmission routes, J. Eur. Acad. Dermatol. Venereol. (2020), https://doi.org/10.1111/jdv.16591.
[21] X. Wang, X. Wu, G. Hu, S. Xia, Z. Sun, Z. Liu, Y. Xie, R. Zhang, S. Jiang, L. Lu, SARS-CoV-2 infects lymphocytes through its spike protein-mediated membrane fusion, Cell. Mol. Immunol. (2020), https://doi.org/10.1038/s41371-020-0422-4.
S. Komine-Aizawa et al.

[28] S.F. Wong, K.M. Chow, T.N. Leung, W.F. Ng, T.K. Ng, C.C. Shek, P.C. Ng, P.W. Lam, L.C. Ho, W.W. To, S.T. Lai, W.W. Yan, P.Y. Tan, Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome, Am. J. Obstet. Gynecol. 191 (1) (2004) 292–297.

[29] G. Editors of Infection, Evolution, SARS-CoV-2 and COVID-19: a genetic, epidemiological, and evolutionary perspective, in: M. Sironi, S.E. Hasnain, B. Rosenthal, T. Phan, F. Luciani, M.A. Shaw, M.E. Mirhashemi, S. Morand, F. Gonzalez-Candelas (Eds.), Infect. Genet. Evol. 84 (2020) 104384.

[30] T. Phan, Genetic diversity and evolution of SARS-CoV-2, Infect. Genet. Evol. 81 (2020) 104260.

[31] M. Becerra-Flores, T. Cardozo, SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate, Int. J. Clin. Pract. (2020) e13525, https://doi.org/10.1111/ijcp.13525.

[32] Q.D. Trinh, N.T. Pham, N.T. Le Nguyen, B.Q. Lam, K.T. Le Phan, K.H. Truong, Y. Izumi, S. Komine-Aizawa, M. Mizuguchi, H. Ushijima, S. Hayakawa, Short communication: drug resistance mutations in the HIV type 1 protease and reverse transcriptase genes in antiretroviral-naïve Vietnamese children, AIDS Res. Hum. Retrovir. 28 (10) (2012) 1305–1307.

[33] I. Yougbare, W.S. Tai, D. Zdravic, B.E. Oswald, S. Lang, G. Zhu, H. Leong-Poi, D. Qu, L. Yu, C. Dunk, J. Zhang, J.G. Sled, S.J. Lye, J. Brikic, C. Peng, P. Hoglund, B. A. Gray, S.L. Aduseum, X.Y. Wen, D.J. Stewart, J. Freedman, H. Ni, Activated NK cells cause placental dysfunction and miscarriages in fetal alloimmune thrombocytopenia, Nat. Commun. 8 (1) (2017) 224.

[34] A. van der Zwan, E.M.W. van der Meer-Prins, P. van Miert, H. van den Heuvel, J.D. H. Anholts, D.L. Roelen, F.H.J. Claas, S. Heidt, Cross-reactivity of virus-specific CD8+ T cells against allogeneic HLA-C: possible implications for pregnancy outcome, Front. Immunol. 9 (2018) 2880.

[35] K. Fuwa, S. Hayakawa, Mechanisms and possible controls of the in utero Zika virus infection: where is the Holy Grail? Am. J. Reprod. Immunol. 77 (2) (2017).